Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2018, Article ID 3038565, 16 pages
https://doi.org/10.1155/2018/3038565
Research Article

Tips and Tricks for Validation of Quality Control Analytical Methods in Good Manufacturing Practice Mesenchymal Stromal Cell Production

1Department of Transfusion Medicine & Hematology, Laboratory of Regenerative Medicine-Cell Factory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
2Department of Clinical Sciences and Community Health, EPIGET Lab, Università degli Studi di Milano, Milan, Italy
3Clinical Laboratory, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

Correspondence should be addressed to Mariele Viganò; ti.im.ocinilcilop@onagiv.eleiram

Received 20 April 2018; Accepted 3 July 2018; Published 4 September 2018

Academic Editor: Huseyin Sumer

Copyright © 2018 Mariele Viganò et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. European Commission, “The rules governing medicinal products in the European Union. Volume 4- Guidelines for good manufacturing practices for medicinal products for human and veterinary use,” 2018, http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm. View at Google Scholar
  2. The European Parliament and the Council of the European Union, “Council Regulation (EC) 1394/2007 of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) no 726/2004. OJEU L 324/121,” http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf.
  3. “European Medicines Agency Guideline on human cell-based medicinal products. EMEA/CHMP/410869/2006,” http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003894.pdf.
  4. ICH Harmonised Tripartite Guideline, “Validation of analytical procedures: text and methodology Q2 (R1),” http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
  5. M. Radrizzani, S. Soncin, S. Bolis, V. Lo Cicero, G. Andriolo, and L. Turchetto, “Quality control assays for clinical-grade human mesenchymal stromal cells: validation strategy,” Methods in Molecular Biology, vol. 1416, pp. 339–356, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Soncin, V. Lo Cicero, G. Astori et al., “A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice,” Journal of Translational Medicine, vol. 7, no. 1, p. 78, 2009. View at Publisher · View at Google Scholar
  7. D. Rustichelli, S. Castiglia, M. Gunetti et al., “Validation of analytical methods in compliance with good manufacturing practice: a practical approach,” Journal of Translational Medicine, vol. 11, no. 1, p. 197, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. T. Camilleri, M. P. Gustafson, A. Dudakovic et al., “Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production,” Stem Cell Research and Therapy, vol. 7, no. 1, p. 107, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. European Commission, “The rules governing medicinal products in the European Union. Volume 4 - Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products,” 2017, https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf. View at Google Scholar
  10. M. Viganò, R. Giordano, and L. Lazzari, “Challenges of running a GMP facility for regenerative medicine in a public hospital,” Regenerative Medicine, vol. 12, no. 7, pp. 803–813, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Giordano, T. Montemurro, M. Viganò et al., “How we make cell therapy in Italy,” Drug Design, Development and Therapy, vol. 9, pp. 4825–4834, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. European Commission, “Eudra Lex. The rules governing medicinal products in the European Union. Volume 4. EU guidelines to good manufacturing practice: medicinal products for human and veterinary use. Annex 13,” Investigational Medicinal Products, http://academy.gmp-compliance.org/guidemgr/files/2009_06_ANNEX13.PDF.
  13. European Pharmacopoeia, Microbiological Control of Cellular Products, 8 edition, 2014, section 2.6.27.
  14. European Pharmacopoeia, Microbiological Examination of Cell-Based Preparations, 9.2 edition, 2017, section 2.6.27.
  15. European Pharmacopoeia, Bacterial Endotoxins, 8 edition, 2014, section 2.6.14.
  16. European Commission, “EudraLex. The rules governing medicinal products in the European Union. Volume 4. EU guidelines to good manufacturing practice: medicinal products for human and veterinary use. Annex 17,” Parametric Release, https://ec.europa.eu/health//sites/health/files/human-use/quality/pc_quality/consultation_document_annex_17.pdf.
  17. P. Gálvez, B. Clares, M. Bermejo, A. Hmadcha, and B. Soria, “Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use,” Stem Cells and Development, vol. 23, no. 10, pp. 1074–1083, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Jimenez, N. Rana, J. Amalraj, K. Walker, and K. Travers, “Validation of the BacT/ALERT(R) 3D system for rapid sterility testing of biopharmaceutical samples,” PDA Journal of Pharmaceutical Science and Technology, vol. 66, no. 1, pp. 38–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Murray, N. McGowan, J. Fleming, and L. Bailey, “Use of the BacT/alert system for rapid detection of microbial contamination in a pilot study using pancreatic islet cell products,” Journal of Clinical Microbiology, vol. 52, no. 10, pp. 3769–3771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. Food and Drug Administration and US Department of Health and Human Services, Guidance for Industry-Pyrogen and Endotoxins Testing: Questions and Answers, 2012.
  21. T. Roch, N. Ma, K. Kratz, and A. Lendlein, “Cell-based detection of microbial biomaterial contaminations,” Clinical Hemorheology and Microcirculation, vol. 60, no. 1, pp. 51–63, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. R. E. Unger, K. Peters, A. Sartoris, C. Freese, and C. J. Kirkpatrick, “Human endothelial cell-based assay for endotoxin as sensitive as the conventional limulus amebocyte lysate assay,” Biomaterials, vol. 35, no. 10, pp. 3180–3187, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. ICH Harmonised Tripartite Guideline, “Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A (R1)”.
  24. J. Gombold, S. Karakasidis, P. Niksa et al., “Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products,” Vaccine, vol. 32, no. 24, pp. 2916–2926, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. European Pharmacopoeia, Nucleated cell count and viability, 8 edition, 2014, section 2.7.29.
  26. M. Gunetti, S. Castiglia, D. Rustichelli et al., “Validation of analytical methods in GMP: the disposable Fast Read 102® device, an alternative practical approach for cell counting,” Journal of Translational Medicine, vol. 10, no. 1, p. 112, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. A. Bravery and A. French, “Reference materials for cellular therapeutics,” Cytotherapy, vol. 16, no. 9, pp. 1187–1196, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Wood, D. Jevremovic, M. C. Béné et al., “Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS, part V: assay performance criteria,” Cytometry Part B: Clinical Cytometry, vol. 84, no. 5, pp. 315–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Galipeau, “The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?” Cytotherapy, vol. 15, no. 1, pp. 2–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. de Wolf, M. van de Bovenkamp, and M. Hoefnagel, “Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy,” Cytotherapy, vol. 19, no. 7, pp. 784–797, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Chinnadurai, D. Rajan, M. Qayed et al., “Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach,” Cell Reports, vol. 22, no. 9, pp. 2504–2517, 2018. View at Publisher · View at Google Scholar · View at Scopus